Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

Regarding joint health, rapid release is more appropriate for acute needs, while the delayed-release formula works for more ongoing support
Additionally, we partner with performance experts, from the NFL to the NCAA, who contribute their elite sports knowledge to bring truly innovative products to market
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Sever AZ, Sever M, Vidovic T, Lojo N, Kolenc D, Vuletic LB, et al
Patients traveling from the Miami area who need documentation for travel can contact our clinic directly for a travel letter